Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 143

1.

Cognitive associations with comprehensive gait and static balance measures in Parkinson's disease.

Morris R, Martini DN, Smulders K, Kelly VE, Zabetian CP, Poston K, Hiller A, Chung KA, Yang L, Hu SC, Edwards KL, Cholerton B, Grabowski TJ, Montine TJ, Quinn JF, Horak F.

Parkinsonism Relat Disord. 2019 Dec;69:104-110. doi: 10.1016/j.parkreldis.2019.06.014. Epub 2019 Jul 4.

PMID:
31731260
2.

Visuospatial functioning is associated with sleep disturbance and hallucinations in nondemented patients with Parkinson's disease.

Specketer K, Zabetian CP, Edwards KL, Tian L, Quinn JF, Peterson-Hiller AL, Chung KA, Hu SC, Montine TJ, Cholerton BA.

J Clin Exp Neuropsychol. 2019 Oct;41(8):803-813. doi: 10.1080/13803395.2019.1623180. Epub 2019 Jun 10.

PMID:
31177941
3.

Effect of Dopaminergic Medications on Blood Oxygen Level-Dependent Variability and Functional Connectivity in Parkinson's Disease and Healthy Aging.

Day TKM, Madhyastha TM, Lee A, Zabetian CP, Montine TJ, Grabowski TJ.

Brain Connect. 2019 Sep;9(7):554-565. doi: 10.1089/brain.2019.0677.

PMID:
31131605
4.

Impact of Pre-Analytical Differences on Biomarkers in the ADNI and PPMI Studies: Implications in the Era of Classifying Disease Based on Biomarkers.

Stewart T, Shi M, Mehrotra A, Aro P, Soltys D, Kerr KF, Zabetian CP, Peskind ER, Taylor P, Shaw LM, Trojanowski JQ, Zhang J; and from the Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2019;69(1):263-276. doi: 10.3233/JAD-190069.

5.

Comparative sensitivity of the MoCA and Mattis Dementia Rating Scale-2 in Parkinson's disease.

Hendershott TR, Zhu D, Llanes S, Zabetian CP, Quinn J, Edwards KL, Leverenz JB, Montine T, Cholerton B, Poston KL.

Mov Disord. 2019 Feb;34(2):285-291. doi: 10.1002/mds.27575. Epub 2018 Dec 10.

PMID:
30776152
6.

The distribution and risk effect of GBA variants in a large cohort of PD patients from Colombia and Peru.

Velez-Pardo C, Lorenzo-Betancor O, Jimenez-Del-Rio M, Moreno S, Lopera F, Cornejo-Olivas M, Torres L, Inca-Martinez M, Mazzetti P, Cosentino C, Yearout D, Waldherr SM, Zabetian CP, Mata IF.

Parkinsonism Relat Disord. 2019 Jun;63:204-208. doi: 10.1016/j.parkreldis.2019.01.030. Epub 2019 Feb 4.

PMID:
30765263
7.

Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases.

Espay AJ, Vizcarra JA, Marsili L, Lang AE, Simon DK, Merola A, Josephs KA, Fasano A, Morgante F, Savica R, Greenamyre JT, Cambi F, Yamasaki TR, Tanner CM, Gan-Or Z, Litvan I, Mata IF, Zabetian CP, Brundin P, Fernandez HH, Standaert DG, Kauffman MA, Schwarzschild MA, Sardi SP, Sherer T, Perry G, Leverenz JB.

Neurology. 2019 Feb 12;92(7):329-337. doi: 10.1212/WNL.0000000000006926. Review.

PMID:
30745444
8.

New windows into the brain: Central nervous system-derived extracellular vesicles in blood.

Shi M, Sheng L, Stewart T, Zabetian CP, Zhang J.

Prog Neurobiol. 2019 Apr;175:96-106. doi: 10.1016/j.pneurobio.2019.01.005. Epub 2019 Jan 25. Review.

PMID:
30685501
9.

Diagnostic Validation for Participants in the Washington State Parkinson Disease Registry.

Kim HM, Leverenz JB, Burdick DJ, Srivatsal S, Pate J, Hu SC, Millard SP, Davis MY, Samii A, Zabetian CP.

Parkinsons Dis. 2018 Nov 1;2018:3719578. doi: 10.1155/2018/3719578. eCollection 2018.

10.

Plasticity-related gene 3 (LPPR1) and age at diagnosis of Parkinson disease.

Wallen ZD, Chen H, Hill-Burns EM, Factor SA, Zabetian CP, Payami H.

Neurol Genet. 2018 Oct 5;4(5):e271. doi: 10.1212/NXG.0000000000000271. eCollection 2018 Oct.

11.

Detecting Mild Cognitive Deficits in Parkinson's Disease: Comparison of Neuropsychological Tests.

Hoogland J, van Wanrooij LL, Boel JA, Goldman JG, Stebbins GT, Dalrymple-Alford JC, Marras C, Adler CH, Junque C, Pedersen KF, Mollenhauer B, Zabetian CP, Eslinger PJ, Lewis SJG, Wu RM, Klein M, Rodriguez-Oroz MC, Cammisuli DM, Barone P, Biundo R, de Bie RMA, Schmand BA, Tröster AI, Burn DJ, Litvan I, Filoteo JV, Geurtsen GJ, Weintraub D; IPMDS Study Group “Validation of Mild Cognitive Impairment in Parkinson Disease”.

Mov Disord. 2018 Nov;33(11):1750-1759. doi: 10.1002/mds.110. Epub 2018 Sep 14. Review.

12.

Stool Immune Profiles Evince Gastrointestinal Inflammation in Parkinson's Disease.

Houser MC, Chang J, Factor SA, Molho ES, Zabetian CP, Hill-Burns EM, Payami H, Hertzberg VS, Tansey MG.

Mov Disord. 2018 May;33(5):793-804. doi: 10.1002/mds.27326. Epub 2018 Mar 23.

13.

Sex differences in progression to mild cognitive impairment and dementia in Parkinson's disease.

Cholerton B, Johnson CO, Fish B, Quinn JF, Chung KA, Peterson-Hiller AL, Rosenthal LS, Dawson TM, Albert MS, Hu SC, Mata IF, Leverenz JB, Poston KL, Montine TJ, Zabetian CP, Edwards KL.

Parkinsonism Relat Disord. 2018 May;50:29-36. doi: 10.1016/j.parkreldis.2018.02.007. Epub 2018 Feb 9.

14.

The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study.

Liu SY, Wile DJ, Fu JF, Valerio J, Shahinfard E, McCormick S, Mabrouk R, Vafai N, McKenzie J, Neilson N, Perez-Soriano A, Arena JE, Cherkasova M, Chan P, Zhang J, Zabetian CP, Aasly JO, Wszolek ZK, McKeown MJ, Adam MJ, Ruth TJ, Schulzer M, Sossi V, Stoessl AJ.

Lancet Neurol. 2018 Apr;17(4):309-316. doi: 10.1016/S1474-4422(18)30032-2. Epub 2018 Feb 16.

15.

Erratum: Variable frequency of LRRK2 variants in the Latin American research consortium on the genetics of Parkinson's disease (LARGE-PD), a case of ancestry.

Cornejo-Olivas M, Torres L, Velit-Salazar MR, Inca-Martinez M, Mazzetti P, Cosentino C, Micheli F, Perandones C, Dieguez E, Raggio V, Tumas V, Borges V, Ferraz HB, Rieder CRM, Shumacher-Schuh A, Velez-Pardo C, Jimenez-Del-Rio M, Lopera F, Chang-Castello J, Andreé-Munoz B, Waldherr S, Yearout D, Zabetian CP, Mata IF.

NPJ Parkinsons Dis. 2018 Jan 19;4:3. doi: 10.1038/s41531-017-0025-1. eCollection 2018.

16.

Homocysteine and cognitive function in Parkinson's disease.

Licking N, Murchison C, Cholerton B, Zabetian CP, Hu SC, Montine TJ, Peterson-Hiller AL, Chung KA, Edwards K, Leverenz JB, Quinn JF.

Parkinsonism Relat Disord. 2017 Nov;44:1-5. doi: 10.1016/j.parkreldis.2017.08.005. Epub 2017 Aug 9.

17.

LARGE-PD: Examining the genetics of Parkinson's disease in Latin America.

Zabetian CP, Mata IF; Latin American Research Consortium on the Genetics of PD (LARGE-PD).

Mov Disord. 2017 Sep;32(9):1330-1331. doi: 10.1002/mds.27081. Epub 2017 Jun 28. No abstract available.

PMID:
28657124
18.

Variable frequency of LRRK2 variants in the Latin American research consortium on the genetics of Parkinson's disease (LARGE-PD), a case of ancestry.

Cornejo-Olivas M, Torres L, Velit-Salazar MR, Inca-Martinez M, Mazzetti P, Cosentino C, Micheli F, Perandones C, Dieguez E, Raggio V, Tumas V, Borges V, Ferraz HB, Rieder CRM, Shumacher-Schuh A, Velez-Pardo C, Jimenez-Del-Rio M, Lopera F, Chang-Castello J, Andreé-Munoz B, Waldherr S, Yearout D, Zabetian CP, Mata IF.

NPJ Parkinsons Dis. 2017 Jun 2;3:19. doi: 10.1038/s41531-017-0020-6. eCollection 2017. Erratum in: NPJ Parkinsons Dis. 2018 Jan 19;4:3.

19.

Association of a neuronal nitric oxide synthase gene polymorphism with levodopa-induced dyskinesia in Parkinson's disease.

Santos-Lobato BL, Borges V, Ferraz HB, Mata IF, Zabetian CP, Tumas V.

Nitric Oxide. 2018 Apr 1;74:86-90. doi: 10.1016/j.niox.2017.06.004. Epub 2017 Jun 8.

PMID:
28602747
20.

Large-scale exploratory genetic analysis of cognitive impairment in Parkinson's disease.

Mata IF, Johnson CO, Leverenz JB, Weintraub D, Trojanowski JQ, Van Deerlin VM, Ritz B, Rausch R, Factor SA, Wood-Siverio C, Quinn JF, Chung KA, Peterson-Hiller AL, Espay AJ, Revilla FJ, Devoto J, Yearout D, Hu SC, Cholerton BA, Montine TJ, Edwards KL, Zabetian CP.

Neurobiol Aging. 2017 Aug;56:211.e1-211.e7. doi: 10.1016/j.neurobiolaging.2017.04.009. Epub 2017 Apr 20.

21.

Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.

Wile DJ, Agarwal PA, Schulzer M, Mak E, Dinelle K, Shahinfard E, Vafai N, Hasegawa K, Zhang J, McKenzie J, Neilson N, Strongosky A, Uitti RJ, Guttman M, Zabetian CP, Ding YS, Adam M, Aasly J, Wszolek ZK, Farrer M, Sossi V, Stoessl AJ.

Lancet Neurol. 2017 May;16(5):351-359. doi: 10.1016/S1474-4422(17)30056-X. Epub 2017 Mar 20.

22.

An alpha-synuclein MRM assay with diagnostic potential for Parkinson's disease and monitoring disease progression.

Yang L, Stewart T, Shi M, Pottiez G, Dator R, Wu R, Aro P, Schuster RJ, Ginghina C, Pan C, Gao Y, Qian W, Zabetian CP, Hu SC, Quinn JF, Zhang J.

Proteomics Clin Appl. 2017 Jul;11(7-8). doi: 10.1002/prca.201700045. Epub 2017 Apr 19.

23.

Intrafamilial variable phenotype including corticobasal syndrome in a family with p.P301L mutation in the MAPT gene: first report in South America.

Gatto EM, Allegri RF, Da Prat G, Chrem Mendez P, Hanna DS, Dorschner MO, Surace EI, Zabetian CP, Mata IF.

Neurobiol Aging. 2017 May;53:195.e11-195.e17. doi: 10.1016/j.neurobiolaging.2017.02.002. Epub 2017 Feb 10.

24.

Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome.

Hill-Burns EM, Debelius JW, Morton JT, Wissemann WT, Lewis MR, Wallen ZD, Peddada SD, Factor SA, Molho E, Zabetian CP, Knight R, Payami H.

Mov Disord. 2017 May;32(5):739-749. doi: 10.1002/mds.26942. Epub 2017 Feb 14.

25.

Common variant rs356182 near SNCA defines a Parkinson's disease endophenotype.

Cooper CA, Jain N, Gallagher MD, Weintraub D, Xie SX, Berlyand Y, Espay AJ, Quinn J, Edwards KL, Montine T, Van Deerlin VM, Trojanowski J, Zabetian CP, Chen-Plotkin AS.

Ann Clin Transl Neurol. 2016 Nov 25;4(1):15-25. doi: 10.1002/acn3.371. eCollection 2017 Jan.

26.

Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis.

Irwin DJ, Grossman M, Weintraub D, Hurtig HI, Duda JE, Xie SX, Lee EB, Van Deerlin VM, Lopez OL, Kofler JK, Nelson PT, Jicha GA, Woltjer R, Quinn JF, Kaye J, Leverenz JB, Tsuang D, Longfellow K, Yearout D, Kukull W, Keene CD, Montine TJ, Zabetian CP, Trojanowski JQ.

Lancet Neurol. 2017 Jan;16(1):55-65. doi: 10.1016/S1474-4422(16)30291-5.

27.

The discovery of LRRK2 p.R1441S, a novel mutation for Parkinson's disease, adds to the complexity of a mutational hotspot.

Mata IF, Davis MY, Lopez AN, Dorschner MO, Martinez E, Yearout D, Cholerton BA, Hu SC, Edwards KL, Bird TD, Zabetian CP.

Am J Med Genet B Neuropsychiatr Genet. 2017 Jan;174(1):113. doi: 10.1002/ajmg.b.32510. Epub 2016 Dec 1. No abstract available.

PMID:
27943640
28.

The Clinical Profile of GBA-Related Lewy Body Disorders.

Zabetian CP.

JAMA Neurol. 2016 Dec 1;73(12):1403-1404. doi: 10.1001/jamaneurol.2016.2546. No abstract available.

PMID:
27723881
29.

Some aspects of the validity of the Montreal Cognitive Assessment (MoCA) for evaluating cognitive impairment in Brazilian patients with Parkinson's disease.

Tumas V, Borges V, Ballalai-Ferraz H, Zabetian CP, Mata IF, Brito MMC, Foss MP, Novaretti N, Santos-Lobato BL.

Dement Neuropsychol. 2016 Oct-Dec;10(4):333-338. doi: 10.1590/s1980-5764-2016dn1004013.

30.

Association of GBA Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease.

Davis MY, Johnson CO, Leverenz JB, Weintraub D, Trojanowski JQ, Chen-Plotkin A, Van Deerlin VM, Quinn JF, Chung KA, Peterson-Hiller AL, Rosenthal LS, Dawson TM, Albert MS, Goldman JG, Stebbins GT, Bernard B, Wszolek ZK, Ross OA, Dickson DW, Eidelberg D, Mattis PJ, Niethammer M, Yearout D, Hu SC, Cholerton BA, Smith M, Mata IF, Montine TJ, Edwards KL, Zabetian CP.

JAMA Neurol. 2016 Oct 1;73(10):1217-1224. doi: 10.1001/jamaneurol.2016.2245.

31.

Arguing against the proposed definition changes of PD.

Boeve BF, Dickson DW, Duda JE, Ferman TJ, Galasko DR, Galvin JE, Goldman JG, Growdon JH, Hurtig HI, Kaufer DI, Kantarci K, Leverenz JB, Lippa CF, Lopez OL, McKeith IG, Singleton AB, Taylor A, Tsuang D, Weintraub D, Zabetian CP.

Mov Disord. 2016 Nov;31(11):1619-1622. doi: 10.1002/mds.26721. Epub 2016 Aug 5.

32.

Identification of genetic modifiers of age-at-onset for familial Parkinson's disease.

Hill-Burns EM, Ross OA, Wissemann WT, Soto-Ortolaza AI, Zareparsi S, Siuda J, Lynch T, Wszolek ZK, Silburn PA, Mellick GD, Ritz B, Scherzer CR, Zabetian CP, Factor SA, Breheny PJ, Payami H.

Hum Mol Genet. 2016 Sep 1;25(17):3849-3862. doi: 10.1093/hmg/ddw206. Epub 2016 Jul 11.

33.

Smoking and haptoglobin phenotype modulate serum ferritin and haptoglobin levels in Parkinson disease.

Costa-Mallen P, Zabetian CP, Hu SC, Agarwal P, Yearout D, Checkoway H.

J Neural Transm (Vienna). 2016 Nov;123(11):1319-1330. Epub 2016 Jun 27.

34.

CNS tau efflux via exosomes is likely increased in Parkinson's disease but not in Alzheimer's disease.

Shi M, Kovac A, Korff A, Cook TJ, Ginghina C, Bullock KM, Yang L, Stewart T, Zheng D, Aro P, Atik A, Kerr KF, Zabetian CP, Peskind ER, Hu SC, Quinn JF, Galasko DR, Montine TJ, Banks WA, Zhang J.

Alzheimers Dement. 2016 Nov;12(11):1125-1131. doi: 10.1016/j.jalz.2016.04.003. Epub 2016 May 24.

35.

DNA variants in CACNA1C modify Parkinson disease risk only when vitamin D level is deficient.

Wang L, Maldonado L, Beecham GW, Martin ER, Evatt ML, Ritchie JC, Haines JL, Zabetian CP, Payami H, Pericak-Vance MA, Vance JM, Scott WK.

Neurol Genet. 2016 Apr 12;2(3):e72. doi: 10.1212/NXG.0000000000000072. eCollection 2016 Jun.

36.

The discovery of LRRK2 p.R1441S, a novel mutation for Parkinson's disease, adds to the complexity of a mutational hotspot.

Mata IF, Davis MY, Lopez AN, Dorschner MO, Martinez E, Yearout D, Cholerton BA, Hu SC, Edwards KL, Bird TD, Zabetian CP.

Am J Med Genet B Neuropsychiatr Genet. 2016 Oct;171(7):925-30. doi: 10.1002/ajmg.b.32452. Epub 2016 Apr 25. Erratum in: Am J Med Genet B Neuropsychiatr Genet. 2017 Jan;174(1):113.

37.

Transcriptomic Profiling of Extracellular RNAs Present in Cerebrospinal Fluid Identifies Differentially Expressed Transcripts in Parkinson's Disease.

Hossein-Nezhad A, Fatemi RP, Ahmad R, Peskind ER, Zabetian CP, Hu SC, Shi M, Wahlestedt C, Zhang J, Faghihi MA.

J Parkinsons Dis. 2016;6(1):109-17. doi: 10.3233/JPD-150737.

38.

Precision Medicine: Clarity for the Complexity of Dementia.

Cholerton B, Larson EB, Quinn JF, Zabetian CP, Mata IF, Keene CD, Flanagan M, Crane PK, Grabowski TJ, Montine KS, Montine TJ.

Am J Pathol. 2016 Mar;186(3):500-6. doi: 10.1016/j.ajpath.2015.12.001. Epub 2015 Dec 24. Review.

39.

Response to the letter "Haptoglobin phenotype and Parkinson disease risk" by Delanghe et al.

Costa-Mallen P, Zabetian CP, Agarwal P, Hu SC, Yearout D, Samii A, Leverenz JB, Roberts JW, Checkoway H.

Parkinsonism Relat Disord. 2016 Jan;22:110-1. doi: 10.1016/j.parkreldis.2015.10.021. No abstract available.

40.

Screening of cognitive impairment in patients with Parkinson's disease: diagnostic validity of the Brazilian versions of the Montreal Cognitive Assessment and the Addenbrooke's Cognitive Examination-Revised.

Sobreira E, Pena-Pereira MA, Eckeli AL, Sobreira-Neto MA, Chagas MH, Foss MP, Cholerton B, Zabetian CP, Mata IF, Tumas V.

Arq Neuropsiquiatr. 2015 Nov;73(11):929-33. doi: 10.1590/0004-282X20150156.

41.

The RAB39B p.G192R mutation causes X-linked dominant Parkinson's disease.

Mata IF, Jang Y, Kim CH, Hanna DS, Dorschner MO, Samii A, Agarwal P, Roberts JW, Klepitskaya O, Shprecher DR, Chung KA, Factor SA, Espay AJ, Revilla FJ, Higgins DS, Litvan I, Leverenz JB, Yearout D, Inca-Martinez M, Martinez E, Thompson TR, Cholerton BA, Hu SC, Edwards KL, Kim KS, Zabetian CP.

Mol Neurodegener. 2015 Sep 24;10:50. doi: 10.1186/s13024-015-0045-4.

42.

GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease.

Mata IF, Leverenz JB, Weintraub D, Trojanowski JQ, Chen-Plotkin A, Van Deerlin VM, Ritz B, Rausch R, Factor SA, Wood-Siverio C, Quinn JF, Chung KA, Peterson-Hiller AL, Goldman JG, Stebbins GT, Bernard B, Espay AJ, Revilla FJ, Devoto J, Rosenthal LS, Dawson TM, Albert MS, Tsuang D, Huston H, Yearout D, Hu SC, Cholerton BA, Montine TJ, Edwards KL, Zabetian CP.

Mov Disord. 2016 Jan;31(1):95-102. doi: 10.1002/mds.26359. Epub 2015 Aug 21.

43.

Haptoglobin phenotype modifies serum iron levels and the effect of smoking on Parkinson disease risk.

Costa-Mallen P, Zabetian CP, Agarwal P, Hu SC, Yearout D, Samii A, Leverenz JB, Roberts JW, Checkoway H.

Parkinsonism Relat Disord. 2015 Sep;21(9):1087-92. doi: 10.1016/j.parkreldis.2015.07.006. Epub 2015 Jul 10.

44.

Letter to the Editor: Hypothesis: Somatic Mosaicism and Parkinson Disease.

Perandones C, Pellene LA, Giugni JC, Calvo DS, Raina GB, Cuevas SM, Mata IF, Zabetian CP, Caputo M, Corach D, Micheli FE, Radrizzani M.

Exp Neurobiol. 2015 Jun;24(2):173-5. doi: 10.5607/en.2015.24.2.173. Epub 2015 Apr 24. No abstract available.

45.

Association of cognitive domains with postural instability/gait disturbance in Parkinson's disease.

Kelly VE, Johnson CO, McGough EL, Shumway-Cook A, Horak FB, Chung KA, Espay AJ, Revilla FJ, Devoto J, Wood-Siverio C, Factor SA, Cholerton B, Edwards KL, Peterson AL, Quinn JF, Montine TJ, Zabetian CP, Leverenz JB.

Parkinsonism Relat Disord. 2015 Jul;21(7):692-7. doi: 10.1016/j.parkreldis.2015.04.002. Epub 2015 Apr 14.

46.

A Peruvian family with a novel PARK2 mutation: Clinical and pathological characteristics.

Cornejo-Olivas MR, Torres L, Mata IF, Mazzetti P, Rivas D, Cosentino C, Inca-Martinez M, Cuba JM, Zabetian CP, Leverenz JB.

Parkinsonism Relat Disord. 2015 May;21(5):444-8. doi: 10.1016/j.parkreldis.2015.01.005. Epub 2015 Jan 15.

47.

Cerebrospinal fluid Aβ42 levels and APP processing pathway genes in Parkinson's disease.

Bekris LM, Tsuang DW, Peskind ER, Yu CE, Montine TJ, Zhang J, Zabetian CP, Leverenz JB.

Mov Disord. 2015 Jun;30(7):936-44. doi: 10.1002/mds.26172. Epub 2015 Mar 24.

48.

Cognitive profile of LRRK2-related Parkinson's disease.

Srivatsal S, Cholerton B, Leverenz JB, Wszolek ZK, Uitti RJ, Dickson DW, Weintraub D, Trojanowski JQ, Van Deerlin VM, Quinn JF, Chung KA, Peterson AL, Factor SA, Wood-Siverio C, Goldman JG, Stebbins GT, Bernard B, Ritz B, Rausch R, Espay AJ, Revilla FJ, Devoto J, Rosenthal LS, Dawson TM, Albert MS, Mata IF, Hu SC, Montine KS, Johnson C, Montine TJ, Edwards KL, Zhang J, Zabetian CP.

Mov Disord. 2015 Apr 15;30(5):728-33. doi: 10.1002/mds.26161. Epub 2015 Feb 4.

49.

Phosphorylated α-synuclein in Parkinson's disease: correlation depends on disease severity.

Stewart T, Sossi V, Aasly JO, Wszolek ZK, Uitti RJ, Hasegawa K, Yokoyama T, Zabetian CP, Leverenz JB, Stoessl AJ, Wang Y, Ginghina C, Liu C, Cain KC, Auinger P, Kang UJ, Jensen PH, Shi M, Zhang J.

Acta Neuropathol Commun. 2015 Jan 31;3:7. doi: 10.1186/s40478-015-0185-3.

50.

Cerebrospinal fluid peptides as potential Parkinson disease biomarkers: a staged pipeline for discovery and validation.

Shi M, Movius J, Dator R, Aro P, Zhao Y, Pan C, Lin X, Bammler TK, Stewart T, Zabetian CP, Peskind ER, Hu SC, Quinn JF, Galasko DR, Zhang J.

Mol Cell Proteomics. 2015 Mar;14(3):544-55. doi: 10.1074/mcp.M114.040576. Epub 2015 Jan 2.

Supplemental Content

Loading ...
Support Center